Advances in stem-cell-generated transplantation therapy for Parkinson's disease

Expert Opinion on Biological Therapy

Volumn 14, Issue 4, 2014, Pages 437-453

  Sundberg, Maria ^a   Isacson, Ole ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cell banking; Cell sorting; Dopaminergic neurons; Good manufacturing practices; Human induced pluripotent stem cells; Neural differentiation; Parkinson's disease; Pluripotent stem cells; Transplantation; Xeno free differentiation

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; GREEN FLUORESCENT PROTEIN; MEMBRANE ANTIGEN;

ANIMAL MODEL; BRAIN CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL POPULATION; CELL SELECTION; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); DOPAMINERGIC NERVE CELL; EMBRYONIC STEM CELL; FETUS CELL; GOOD MANUFACTURING PRACTICE; GRAFT DYSFUNCTION; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; MESENCEPHALON; NONHUMAN; PARKINSON DISEASE; PLURIPOTENT STEM CELL; PURIFICATION; REVIEW; STEM CELL TRANSPLANTATION; XENO-FREE CULTURE;

ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; HUMANS; MICE; MPTP POISONING; PARKINSON DISEASE; PLURIPOTENT STEM CELLS; PRIMATES; RATS; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 84896105350     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2014.876986     Document Type: Review

References (105)

1. Trinh J, Farrer M. Advances in the genetics of Parkinson disease. Nat Rev Neurol 2013;9:445-54
2. Lang AE, Lozano AM. Parkinson's disease. Second of two parts. N Engl J Med 1998;339:1130-43
3. Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med 1998;339:1044-53
4. Langston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol 2006;59:591-6
5. Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008;23:837-44
6. Deleidi M, Cooper O, Hargus G, et al. Oct4-induced reprogramming is required for adult brain neural stem cell differentiation into midbrain dopaminergic neurons. PLoS One 2011;6:e19926
7. Bergmann O, Liebl J, Bernard S, et al. The age of olfactory bulb neurons in humans. Neuron 2012;74:634-9
8. Bhardwaj RD, Curtis MA, Spalding KL, et al. Neocortical neurogenesis in humans is restricted to development. Proc Natl Acad Sci USA 2006;103:12564-8
9. Spalding KL, Bhardwaj RD, Buchholz BA, et al. Retrospective birth dating of cells in humans. Cell 2005;122:133-43
10. Bjorklund LM, Sanchez-Pernaute R, Chung S, et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation into a Parkinson rat model. Proc Natl Acad Sci USA 2002;99:2344-9
11. Kriks S, Shim JW, Piao J, et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 2011;480:547-51
12. Kirkeby A, Grealish S, Wolf DA, et al. Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions. Cell Rep 2012;1:703-14
13. Ma Y, Tang C, Chaly T, et al. Dopamine cell implantation in Parkinson's disease: long-term clinical and (18)F-FDOPA PET outcomes. J Nucl Med 2010;51:7-15
14. Isacson O, Deacon T. Neural transplantation studies reveal the brain's capacity for continuous reconstruction. Trends Neurosci 1997;20:477-82
15. Isacson O, Deacon TW. Specific axon guidance factors persist in the adult brain as demonstrated by pig neuroblasts transplanted to the rat. Neuroscience 1996;75:827-37
16. Cooper O, Hargus G, Deleidi M, et al. Differentiation of human ES and Parkinson's disease iPS cells into ventral midbrain dopaminergic neurons requires a high activity form of SHH, FGF8a and specific regionalization by retinoic acid. Mol Cell Neurosci 2010;45:258-66
17. Hargus G, Cooper O, Deleidi M, et al. Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc Natl Acad Sci USA 2010;107:15921-6
18. Sundberg M, Bogetofte H, Lawson T, et al. Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. Stem Cells 2013;31:1548-62
19. Redmond DE Jr, Vinuela A, Kordower JH, et al. Influence of cell preparation and target location on the behavioral recovery after striatal transplantation of fetal dopaminergic neurons in a primate model of Parkinson's disease. Neurobiol Dis 2008;29:103-16
20. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001;344:710-19
21. Mendez I, Vinuela A, Astradsson A, et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat Med 2008;14:507-9
22. Hauser RA, Freeman TB, Snow BJ, et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol 1999;56:179-87
23. Politis M, Wu K, Loane C, et al. Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci Transl Med 2010;2:38ra46
24. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003;54:403-14
25. Hagell P, Piccini P, Bjorklund A, et al. Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci 2002;5:627-8
26. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998;282:1145-7
27. Reubinoff BE, Pera MF, Fong CY, et al. Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat Biotechnol 2000;18:399-404
28. Mallon BS, Park KY, Chen KG, et al. Toward xeno-free culture of human embryonic stem cells. Int J Biochem Cell Biol 2006;38:1063-75
29. Buzzard JJ, Gough NM, Crook JM, et al. Karyotype of human ES cells during extended culture. Nat Biotechnol 2004;22:381-2; author reply 382
30. Xi J, Liu Y, Liu H, et al. Specification of midbrain dopamine neurons from primate pluripotent stem cells. Stem Cells 2012;30:1655-63
31. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-72
32. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318:1917-20
33. Nakagawa M, Koyanagi M, Tanabe K, et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 2008;26:101-6
34. Ban H, Nishishita N, Fusaki N, et al. Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors. Proc Natl Acad Sci USA 2011;108:14234-9
35. Stadtfeld M, Nagaya M, Utikal J, et al. Induced pluripotent stem cells generated without viral integration. Science 2008;322:945-9
36. Okita K, Nakagawa M, Hyenjong H, et al. Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008;322:949-53
37. Woltjen K, Michael IP, Mohseni P, et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009;458:766-70
38. Okita K, Matsumura Y, Sato Y, et al. A more efficient method to generate integration-free human iPS cells. Nat Methods 2011;8:409-12
39. Efe JA, Ding S. The evolving biology of small molecules: controlling cell fate and identity. Philos Trans R Soc Lond B Biol Sci 2011;366:2208-21
40. Zhou H, Wu S, Joo JY, et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009;4:381-4
41. Soldner F, Hockemeyer D, Beard C, et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009;136:964-77
42. Imaizumi Y, Okada Y, Akamatsu W, et al. Mitochondrial dysfunction associated with increased oxidative stress and alpha-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue. Mol Brain 2012;5:35
43. Sanchez-Danes A, Richaud-Patin Y, Carballo-Carbajal I, et al. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol Med 2012;4:380-95
44. Devine MJ, Ryten M, Vodicka P, et al. Parkinson's disease induced pluripotent stem cells with triplication of the alphasynuclein locus. Nat Commun 2011;2:440
45. Cooper O, Seo H, Andrabi S, et al. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci Transl Med 2012;4:141ra190
46. Ono Y, Nakatani T, Sakamoto Y, et al. Differences in neurogenic potential in floor plate cells along an anteroposterior location: midbrain dopaminergic neurons originate from mesencephalic floor plate cells. Development 2007;134:3213-25
47. Fasano CA, Chambers SM, Lee G, et al. Efficient derivation of functional floor plate tissue from human embryonic stem cells. Cell Stem Cell 2010;6:336-47
48. Chambers SM, Fasano CA, Papapetrou EP, et al. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol 2009;27:275-80
49. Castelo-Branco G, Rawal N, Arenas E. GSK-3beta inhibition/beta-catenin stabilization in ventral midbrain precursors increases differentiation into dopamine neurons. J Cell Sci 2004;117:5731-7
50. Ferri AL, Lin W, Mavromatakis YE, et al. Foxa1 and Foxa2 regulate multiple phases of midbrain dopaminergic neuron development in a dosage-dependent manner. Development 2007;134:2761-9
51. Nakatani T, Kumai M, Mizuhara E, et al. Lmx1a and Lmx1b cooperate with Foxa2 to coordinate the specification of dopaminergic neurons and control of floor plate cell differentiation in the developing mesencephalon. Dev Biol 2010;339:101-13
52. Saucedo-Cardenas O, Quintana-Hau JD, Le WD, et al. Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc Natl Acad Sci USA 1998;95:4013-18
53. Peng C, Aron L, Klein R, et al. Pitx3 is a critical mediator of GDNF-induced BDNF expression in nigrostriatal dopaminergic neurons. J Neurosci 2011;31:12802-15
54. Thompson L, Barraud P, Andersson E, et al. Identification of dopaminergic neurons of nigral and ventral tegmental area subtypes in grafts of fetal ventral mesencephalon based on cell morphology, protein expression, and efferent projections. J Neurosci 2005;25:6467-77
55. Mendez I, Sanchez-Pernaute R, Cooper O, et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain 2005;128:1498-510
56. Ganat YM, Calder EL, Kriks S, et al. Identification of embryonic stem cell-derived midbrain dopaminergic neurons for engraftment. J Clin Invest 2012;122:2928-39
57. Sonntag KC, Pruszak J, Yoshizaki T, et al. Enhanced yield of neuroepithelial precursors and midbrain-like dopaminergic neurons from human embryonic stem cells using the bone morphogenic protein antagonist noggin. Stem Cells 2007;25:411-18
58. Doi D, Morizane A, Kikuchi T, et al. Prolonged maturation culture favors a reduction in the tumorigenicity and the dopaminergic function of human ESC-derived neural cells in a primate model of Parkinson's disease. Stem Cells 2012;30:935-45
59. Pruszak J, Ludwig W, Blak A, et al. CD15, CD24, and CD29 define a surface biomarker code for neural lineage differentiation of stem cells. Stem Cells 2009;27:2928-40
60. Sundberg M, Jansson L, Ketolainen J, et al. CD marker expression profiles of human embryonic stem cells and their neural derivatives, determined using flowcytometric analysis, reveal a novel CD marker for exclusion of pluripotent stem cells. Stem Cell Res 2009;2:113-24
61. Pruszak J, Sonntag KC, Aung MH, et al. Markers and methods for cell sorting of human embryonic stem cell-derived neural cell populations. Stem Cells 2007;25:2257-68
62. Knoepfler PS. Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine. Stem Cells 2009;27:1050-6
63. Politis M, Oertel WH, Wu K, et al. Graft-induced dyskinesias in Parkinson's disease: high striatal serotonin/dopamine transporter ratio. Mov Disord 2011;26:1997-2003
64. Hedlund E, Pruszak J, Lardaro T, et al. Embryonic stem cell-derived Pitx3- enhanced green fluorescent protein midbrain dopamine neurons survive enrichment by fluorescence-activated cell sorting and function in an animal model of Parkinson's disease. Stem Cells 2008;26:1526-36
65. Ni HT, Hu S, Sheng WS, et al. High-level expression of functional chemokine receptor CXCR4 on human neural precursor cells. Brain Res Dev Brain Res 2004;152:159-69
66. Sundberg M, Andersson PH, Akesson E, et al. Markers of pluripotency and differentiation in human neural precursor cells derived from embryonic stem cells and CNS tissue. Cell Transplant 2011;20:177-91
67. Yuan SH, Martin J, Elia J, et al. Cell-surface marker signatures for the isolation of neural stem cells, glia and neurons derived from human pluripotent stem cells. PLoS One 2011;6:e17540
68. Sundberg M, Skottman H, Suuronen R, et al. Production and isolation of NG2+ oligodendrocyte precursors from human embryonic stem cells in defined serumfree medium. Stem Cell Res 2010;5:91-103
69. Sundberg M, Hyysalo A, Skottman H, et al. A xeno-free culturing protocol for pluripotent stem cell-derived oligodendrocyte precursor cell production. Regen Med 2011;6:449-60
70. Langston JW, Ballard P, Tetrud JW, et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-80
71. Kolata G. Monkey model of Parkinson's disease. Science 1983;220:705
72. Saiki H, Hayashi T, Takahashi R, et al. Objective and quantitative evaluation of motor function in a monkey model of Parkinson's disease. J Neurosci Methods 2010;190:198-204
73. Decamp E, Schneider JS. Effects of nicotinic therapies on attention and executive functions in chronic low-dose MPTP-treated monkeys. Eur J Neurosci 2006;24:2098-104
74. Doudet D, Gross C, Lebrun-Grandie P, et al. MPTP primate model of Parkinson's disease: a mechanographic and electromyographic study. Brain Res 1985;335:194-9
75. Bezard E, Imbert C, Deloire X, et al. A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey. Brain Res 1997;766:107-12
76. Kortekaas R, Eshuis SA, Andringa G, et al. Motor behavior correlates with striatal [(1)(8)F]-DOPA uptake in MPTP-lesioned primates. Neurochem Int 2013;62:349-53
77. Blesa J, Juri C, Collantes M, et al. Progression of dopaminergic depletion in a model of MPTP-induced Parkinsonism in non-human primates. An (18)FDOPA and (11)C-DTBZ PET study. Neurobiol Dis 2010;38:456-63
78. Bohnen NI, Albin RL, Koeppe RA, et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab 2006;26:1198-212
79. Emborg ME, Zhang Z, Joers V, et al. Intracerebral transplantation of differentiated human embryonic stem cells to hemiparkinsonian monkeys. Cell Transplant 2013;22:831-8
80. Cicchetti F, Fodor W, Deacon TW, et al. Immune parameters relevant to neural xenograft survival in the primate brain. Xenotransplantation 2003;10:41-9
81. Deleidi M, Hargus G, Hallett P, et al. Development of histocompatible primate-induced pluripotent stem cells for neural transplantation. Stem Cells 2011;29:1052-63
82. Emborg ME, Liu Y, Xi J, et al. Induced pluripotent stem cell-derived neural cells survive and mature in the nonhuman primate brain. Cell Rep 2013;3:646-50
83. Hallett P, Deleidi M, Astradsson A, et al. Long-term function and survival of Cynomolgus monkey iPS cell-derived dopamine neurons following autologous transplantation in a non-human primate model of Parkinson's disease. Society for Neuroscience Annual Meeting 2013; San Diego, CA, USA; 2013
84. Ahrlund-Richter L, De Luca M, Marshak DR, et al. Isolation and production of cells suitable for human therapy: challenges ahead. Cell Stem Cell 2009;4:20-6
85. Opelz G, Wujciak T, Dohler B, et al. HLA compatibility and organ transplant survival. Collaborative Transplant Study. Rev Immunogenet 1999;1:334-42
86. Taylor CJ, Bolton EM, Bradley JA. Immunological considerations for embryonic and induced pluripotent stem cell banking. Philos Trans R Soc Lond B Biol Sci 2011;366:2312-22
87. Drukker M, Katz G, Urbach A, et al. Characterization of the expression of MHC proteins in human embryonic stem cells. Proc Natl Acad Sci USA 2002;99:9864-9
88. Taylor CJ, Bolton EM, Pocock S, et al. Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching. Lancet 2005;366:2019-25
89. Kim K, Doi A, Wen B, et al. Epigenetic memory in induced pluripotent stem cells. Nature 2010;467:285-90
90. Okano H, Nakamura M, Yoshida K, et al. Steps toward safe cell therapy using induced pluripotent stem cells. Circ Res 2013;112:523-33
91. Zhao T, Zhang ZN, Rong Z, et al. Immunogenicity of induced pluripotent stem cells. Nature 2011;474:212-15
92. Sanders LH, Laganiere J, Cooper O, et al. LRRK2 mutations cause mitochondrial DNA damage in iPSCderived neural cells from Parkinson's disease patients: reversal by gene correction. Neurobiol Dis 2013;62C:381-6
93. Adewumi O, Aflatoonian B, Ahrlund-Richter L, et al. Characterization of human embryonic stem cell lines by the International Stem Cell Initiative. Nat Biotechnol 2007;25:803-16
94. Martin MJ, Muotri A, Gage F, et al. Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nat Med 2005;11:228-32
95. Heiskanen A, Satomaa T, Tiitinen S, et al. N-glycolylneuraminic acid xenoantigen contamination of human embryonic and mesenchymal stem cells is substantially reversible. Stem Cells 2007;25:197-202
96. Rajala K, Lindroos B, Hussein SM, et al. A defined and xeno-free culture method enabling the establishment of clinicalgrade human embryonic, induced pluripotent and adipose stem cells. PLoS One 2010;5:e10246
97. International Stem Cell Initiative C, Akopian V, Andrews PW, et al. Comparison of defined culture systems for feeder cell free propagation of human embryonic stem cells. In Vitro Cell Dev Biol Anim 2010;46:247-58
98. Heng BC, Li J, Chen AK, et al. Translating human embryonic stem cells from 2-dimensional to 3-dimensional cultures in a defined medium on laminin- and vitronectin-coated surfaces. Stem Cells Dev 2012;21:1701-15
99. Chen G, Gulbranson DR, Hou Z, et al. Chemically defined conditions for human iPSC derivation and culture. Nat Methods 2011;8:424-9
100. Tannenbaum SE, Turetsky TT, Singer O, et al. Derivation of xeno-free and GMP-grade human embryonic stem cells - platforms for future clinical applications. PLoS One 2012;7:e35325
101. Crook JM, Peura TT, Kravets L, et al. The generation of six clinical-grade human embryonic stem cell lines. Cell Stem Cell 2007;1:490-4
102. Stephenson E, Jacquet L, Miere C, et al. Derivation and propagation of human embryonic stem cell lines from frozen embryos in an animal product-free environment. Nat Protoc 2012;7:1366-81
103. Ilic D, Stephenson E, Wood V, et al. Derivation and feeder-free propagation of human embryonic stem cells under xenofree conditions. Cytotherapy 2012;14:122-8
104. Kuleshova LL, Tan FC, Magalhaes R, et al. Effective cryopreservation of neural stem or progenitor cells without serum or proteins by vitrification. Cell Transplant 2009;18:135-44
105. Morizane A DD, Kikuchi T, Okita K, et al. Direct comparison of autologous and allogeneic transplantation of iPSCderived neural cells in the brain of a nonhuman primate. Stem Cell Reports 2013;1:283-92